Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents

Diabetology and Metabolic Syndrome

Volumn 6, Issue 1, 2014, Pages

  Li, Chun Jun ^a   Liu, Xiao Juan ^a   Bai, Lian ^a   Yu, Qian ^a   Zhang, Qiu Mei ^a   Yu, Pei ^a   Yu, De Min ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

DPP 4 inhibitors; Glycemic control; OHAs; Type 2 diabetes mellitus

Indexed keywords

ACARBOSE; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; VILDAGLIPTIN;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BODY MASS; BODY WEIGHT; CHINESE; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPERTRANSAMINASEMIA; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; THORAX PAIN;

EID: 84902553760     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/1758-5996-6-69     Document Type: Article

References (47)

1. Prevalence of diabetes among men and women in China. Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, Shan Z, Liu J, Tian H, Ji Q, Zhu D, Ge J, Lin L, Chen L, Guo X, Zhao Z, Li Q, Zhou Z, Shan G, He J, China National Diabetes and Metabolic Disorders Study Group, N Engl J Med 2010 12 1090 1101
2. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). Turner RC, Cull CA, Frighi V, Holman RR, UK Prospective Diabetes Study (UKPDS) Group, JAMA 1999 281 2005 2012 10.1001/jama.281.21.2005 10359389
3. Global and societal implications of the diabetes epidemic. Zimmet P, Alberti KG, Shaw J, Nature 2001 414 782 787 10.1038/414782a 11742409
4. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Wild S, Roglic G, Green A, Sicree R, King H, Diabetes Care 2004 27 1047 1053 10.2337/diacare.27.5.1047 15111519
5. China guideline for type 2 diabetes. Chinese Diabetes Society, Chin J Diabetes Mellitus 2010 13 suppl 2 6 56
6. Standards of medical care in diabetes-2013. American Diabetes Association, Diabetes Care 2013 13 suppl 1 11 S66
7. Projected and observed diabetes epidemics in China and beyond. Zhao D, Zhao F, Li Y, Zheng Z, Curr Cardiol Rep 2012 13 106 111
8. Asian-Pacific Type 2 Diabetes Policy Group, Type 2 diabetes: practical targets and treatments Melbourne/Singapore: International Diabetes Institute (IDI)/In Vivo Communications (Asia) Pte Limited 4 http://www.idf.org/webdata/ docs/T2D-practical-tt.pdf; 2005 [accessed 7.07.10]
9. International Diabetes Federation, Clinical guidelines task force, global guideline for type 2 diabetes Brussels, Belgium: International Diabetes Federation http://www.idf.org/webdata/docs/IDF%20GGT2D.pdf; 2005 [accessed 7.07.10]
10. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. DeFronzo RA, Diabetes 2009 58 4 773 795 10.2337/db09-9028 19336687
11. Statement by an American Association of Clinical Endocrinologists/ American College of Endocrinology Consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G, Handelsman Y, Horton ES, Lebovitz H, Levy P, Moghissi ES, Schwartz SS, Endocr Pract 2009 15 6 540 559 10.4158/EP.15.6.540 19858063
12. New drugs for the treatment of diabetes: part II: incretin-based therapy and beyond. Inzucchi SE, McGuire DK, Circulation 2008 117 574 584 10.1161/CIRCULATIONAHA.107.735795 18227398
13. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with up titration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Chacra AR, Tan GH, Apanovitch A, Ravichandran S, List J, Chen R, Int J Clin Pract 2009 63 1395 1406 10.1111/j.1742-1241.2009.02143.x 19614786
14. Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin up-titration in Chinese patients with type 2 diabetes mellitus: study design and rationale of the vision study. Ji LN, Pan CY, Lu JM, Li H, Li Q, Li QF, Peng YD, Tian HM, Yao C, Zhao ZG, Zhang RY, Wang XL, Wang L, VISION Study Group, Cardiovasc Diabetol 2013 12 118 10.1186/1475-2840-12-118 23958390
15. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Ferrannini E, Fonseca V, Zinman B, Matthews D, Ahrén B, Byiers S, Shao Q, Dejager S, Diabetes Obes Metab 2009 11 2 157 166 10.1111/j.1463-1326.2008.00994.x 19125777
16. Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial. Iwamoto Y, Tajima N, Kadowaki T, Nonaka K, Taniguchi T, Nishii M, Arjona Ferreira JC, Amatruda JM, Diabetes Obes Metab 2010 12 613 622 10.1111/j.1463-1326.2010.01197.x 20590736
17. Comparative study of sitagliptin with pioglitazone in Japanese type 2 diabetic patients: the COMPASS randomized controlled trial. Takihata M, Nakamura A, Tajima K, Inazumi T, Komatsu Y, Tamura H, Yamazaki S, Kondo Y, Yamada M, Kimura M, Terauchi Y, Diabetes Obes Metab 2013 15 5 455 462 10.1111/dom.12055 23279373
18. Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. Cervera A, Wajcberg E, Sriwijitkamol A, Fernandez M, Zuo P, Triplitt C, Musi N, DeFronzo RA, Cersosimo E, Am J Physiol Endocrinol Metab 2008 294 846 E852 10.1152/ajpendo.00030.2008 18334612
19. Effect of exenatide on splanchnic and peripheral glucose metabolism in type 2 diabetic subjects. Cersosimo E, Gastaldelli A, Cervera A, Wajcberg E, Sriwijilkamol A, Fernandez M, Zuo P, Petz R, Triplitt C, Musi N, DeFronzo RA, J Clin Endocrinol Metab 2011 96 1763 1770 10.1210/jc.2010-2146 21411546
20. Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type2 diabetes: a review of recent clinical trials. Karasik A, Aschner P, Katzeff H, Davies MJ, Stein PP, Curr Med Res Opin 2008 24 489 496 10.1185/030079908X261069 18182122
21. Efficacy and safety of saxagliptin in drug-naïve Asian patients with type 2 diatetes mellitus: a randomized controlled trial. Pan CY, Yang W, Tou C, Gause-Nilsson I, Zhao J, Diabetes Metab Res Rev 2012 28 3 268 275 10.1002/dmrr.1306 22081481
22. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Nonaka K, Kakikawa T, Sato A, Okuyama K, Fujimoto G, Kato N, Suzuki H, Hirayama Y, Ahmed T, Davies MJ, Stein PP, Diabetes Res Clin Pract 2008 79 291 298 10.1016/j.diabres.2007.08.021 17933414
23. Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus. Kikuchia M, Abe N, Kato M, Terao S, Mimori N, Tachibana H, Diabetes Res Clin Pract 2009 83 233 240 10.1016/j.diabres.2008.10.006 19118913
24. Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus. Pan C, Xing X, Han P, Zheng S, Ma J, Liu J, Lv X, Lu J, Bader G, Institution Investigators, Diabetes Obes Metab 2012 14 8 737 744 10.1111/j.1463-1326.2012.01593.x 22369287
25. Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with Type 2 diabetes mellitus. Kikuchi M, Haneda M, Koya D, Tobe K, Onishi Y, Couturier A, Mimori N, Inaba Y, Goodman M, Diabetes Res Clin Pract 2010 89 216 223 10.1016/j.diabres.2010.04.017 20537746
26. Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: a randomized controlled trial. Yang W, Chang Yu P, Tou C, Zhao J, Gause-Nilsson I, Diabetes Res Clin Pract 2011 94 217 224 10.1016/j.diabres.2011.07.035 21871686
27. Efficacy of Sitagliptin when added to ongoing therapy in Korean subjects with type 2 diabetes mellitus. Soo Chung H, Kyu Lee M, Diabetes Metab J 2011 35 411 417 10.4093/dmj.2011.35.4.411 21977462
28. Efficacy of sitagliptin on blood glucose fluctuation in Japanese type 2 diabetic patients with basal-supported oral therapy. Takahara M, Shiraiwa T, Kaneto H, Katakami N, Matsuoka TA, Shimomura I, Endocr J 2012 59 12 1131 1136 10.1507/endocrj.EJ12-0220 22850206
29. Once-daily saxagliptin monotherapy improves glycemic control in drug-naive patients with type 2 diabetes. Rosenstock J, Aguilar-Salinas CA, Klein E, Diabetes 2008 57 suppl 1 154
30. Vildagliptin in drug-naive patients with type 2 diabetes: a 24 week double-blind, randomized, placebo-controlled, multiple-dose study. Dejager S, Razac S, Foley JE, Schweizer A, Horm Metab Res 2007 39 218 223 10.1055/s-2007-970422 17373638
31. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE, Sitagliptin Study 021 Group, Diabetes Care 2006 29 2632 2637 10.2337/dc06-0703 17130196
32. Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin-diabetes control and potential adverse events. Ahre'n B, Best Pract Res Clin Endocrinol Metab 2009 23 487 498 10.1016/j.beem.2009.03.003 19748066
33. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes on metformin alone. DeFronzo RA, Hissa MN, Garber AJ, Luiz Gross J, Yuyan Duan R, Ravichandran S, Chen RS, Saxagliptin 014 Study Group, Diabetes Care 2009 32 1649 1655 10.2337/dc08-1984 19478198
34. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G, Diabetes Care 2006 29 2638 2643 10.2337/dc06-0706 17130197
35. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Scott R, Loeys T, Davies MJ, Engel SS, Diabetes Obes Metab 2008 10 959 969 10.1111/j.1463-1326.2007.00839.x 18201203
36. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Raz I, Chen Y, Wu M, Hussain S, Kaufman KD, Amatruda JM, Langdon RB, Stein PP, Alba M, Curr Med Res Opin 2008 24 537 550 10.1185/030079908X260925 18194595
37. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Garber AJ, Foley JE, Banerji MA, Ebeling P, Gudbjörnsdottir S, Camisasca RP, Couturier A, Baron MA, Diabetes Obes Metab 2008 10 1047 1056 10.1111/j.1463-1326.2008.00859.x 18284434
38. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P, Sitagliptin Study 035 Group, Diabetes Obes Metab 2007 9 733 745 10.1111/j.1463-1326.2007.00744.x 17593236
39. Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial. Pan C, Yang W, Barona JP, Wang Y, Niggli M, Mohideen P, Wang Y, Foley JE, Diabet Med 2008 25 435 441 10.1111/j.1464-5491.2008.02391.x 18341596
40. Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naïve patients with Type 2 diabetes. Schweizer A, Couturier A, Foley JE, Dejager S, Diabet Med 2007 24 9 955 961 10.1111/j.1464-5491.2007.02191.x 17509069
41. Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study. Guerci B, Monnier L, Serusclat P, Petit C, Valensi P, Huet D, Raccah D, Colette C, Quéré S, Dejager S, Diabetes Metab 2012 38 4 359 366 10.1016/j.diabet.2012.06.001 22809630
42. Comparative efficacy of Vildagliptin and Sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials. Signorovitch JE, Wu EQ, Swallow E, Kantor E, Fan L, Gruenberger JB, Clin Drug Investig 2011 31 9 665 674 10.2165/11592490-000000000- 00000 21819162
43. Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Iwamoto Y, Taniguchi T, Nonaka K, Okamoto T, Okuyama K, Arjona Ferreira JC, Amatruda J, Endocr J 2010 57 5 383 394 10.1507/endocrj.K09E-272 20332588
44. Vildagliptin dosedependently improves glycemic control in Japanese patients with type 2 diabetes mellitus. Kikuchi M, Abe N, Kato M, Terao S, Mimori N, Tachibana H, Diabetes Res Clin Pract 2009 83 2 233 240 10.1016/j.diabres.2008.10.006 19118913
45. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP, Sitagliptin Study 024 Group, Diabetes Obes Metab 2007 9 194 205 10.1111/j.1463-1326.2006.00704.x 17300595
46. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE, Sitagliptin 036 Study Group, Diabetes Care 2007 30 1979 1987 10.2337/dc07-0627 17485570
47. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Rosenstock J, Sankoh S, List JF, Diabetes Obes Metab 2008 10 376 386 10.1111/j.1463-1326.2008.00876.x 18355324